Mesenchymal Stem Cell Therapy in Type 1 Diabetes Mellitus and Its Main Complications: From Experimental Findings to Clinical Practice

Ezquer, Marcelo; Arango-Rodríguez, Martha L.; Giraud-Billoud, Maximiliano; Fern,; Ezquer, o

doi:10.4172/2157-7633.1000227

Cited by 19 publications

(17 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The embryonic and adult stem cells have been used for the production of insulin producing cells derived from amniotic fluid, bone marrow and adipose tissue. DPSCs have the capacity to differentiate into islet-like aggregates also shown by some groups (43,44).…”

Section: Type 1 Diabetesmentioning

confidence: 55%

“…Dental pulp is ideal for tissue engineering, for clinical use in several pathologies requiring bone tissue growth and repair. This group of researchers even stated that "if the bone marrow is considered as the site of first choice for hematopoietic stem cell collection, dental pulp must be considered as one of the major sites for mesenchymal cell collection" (44).…”

Section: Resultsmentioning

confidence: 99%

“…Today, any population of cell that meets the following attributes, irrespective of their source, is generally referred to as MSC: morphologically, they have the tendency to adhere to plastic and have a fibroblastlike appearance; functionally, they have the ability of express more than 95% of the population express the CD105, CD73, CD90 surface antigens and that less than 2% of the population of the cells express the panleukocyte marker CD45, the hematopoietic progenitor and endothelial cell marker CD34 (44).…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Human Dental Pulp Stem Cells – A Prospective Regenerative Therapy

Tiwari¹

2018

IJTSRD

View full text Add to dashboard Cite

Stem cells are the pluripotent cells that possess the potential to differentiate into a variety of cells of the human body. The knowledge of stem cell is enhancing not only in the medical field but equally in the dental field too. The stem cells of the dental origin provide remedies to many cell-based therapies in the regenerative medicine. Dental pulp stem cells (DPSCs) possess the mesenchymal stem cells phenotype and therefore get differentiated into neuron, chondrocytes, cardiomyocytes. The demand of cry preserving human exfoliated deciduous teeth (SHED) cells or the DPSCs are gaining popularity, in a similar fashion of the umbilical cord blood storage. The dental pulp stem cells are the adult multipotent cells that thrive in the cell abundant zone of the dental pulp. Accordingly, this multipotent characteristic makes the DPSCs an apt model to be incorporated in both dental and medical applications respectively. Therefore, this review which has been executed by both the electronic and hand-searching tools provides an outline of the applications of the dental pulp stem cells in the treatment of various medical disorders, nevertheless other aspects like the long-term clinical trials and studies needs more investigation to ascertain their efficacy.

show abstract

Section: Type 1 Diabetesmentioning

confidence: 55%

Section: Resultsmentioning

confidence: 99%

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Human Dental Pulp Stem Cells – A Prospective Regenerative Therapy

Tiwari¹

2018

IJTSRD

View full text Add to dashboard Cite

show abstract

“…Autoimmune destruction of B-Cells is a hallmark of type 1 diabetes (T1D). Immunomodulatory and proangiogenic roles of MSCs are used in this protocol to arrest β-cell destruction, preserve residual β-cell mass and prevent disease recurrence [5]. Secondly the ICAs derived from the ADMSCs further help in the control of blood sugar levels by producing Insulin.…”

Section: Type I Diabetesmentioning

confidence: 99%

Therapeutic Application of Autologous ADMSCS (Adipose Derived Mesenchymal Stem Cells) and Islet like Cell Aggregates (ICAS) Derived from them in Type 1 and 2 Diabetes Mellitus - A Proof of Concept Study

Marathe¹

2016

SRDT

View full text Add to dashboard Cite

Background: The concept is based upon the properties of mesenchymal stem cells like angiogenesis, anti-inflammatory, immune-modulatory as well as trans-lineage translation of ADMSCs to ICAs and the hypothesis of multiple Intramuscular injections (IM) of Mesenchymal Stromal Cells (MSCs) at different sites would aid in countering the insulin resistance. This is a proof of concept report of treatment of seven patients, 2 with type I & 5 with type II Diabetes. Material and methods: 7 patients were enrolled (2 with type 1 and 5 with type 2) randomly. About 100 to 300 cc of adipose tissue was aspirated from lower abdomen and processed to obtain mononuclear cells. Mononuclear cells were divided into two parts. Half of the mononuclear cells (SVF-Stromal Vascular Factor) were injected intramuscularly (dosage: 1-2 million cells per kg/body weight) and the other half were processed for culture. The pure cultures of MSCs were passaged twice to get more number of cells. The protocol for MSCs isolation was established by phenotypic characterization of MSCS by surface markers. About 20 million of ADMSCs were translated to ICAs. This yielded up to 1000 ICAs. The ICAs were also characterized by their surface markers like Insulin and c-peptide and their insulin production after glucose challenge. ICAs were then injected intra hepatically through percutaneous route. Result: The dosage of insulin decreased after intra muscular injection of ADMSCs combined with intra-hepatic injection of ICAs. No adverse effects including GVHD were noticed following the procedure. Conclusion: All the 7 patients were benefitted and were satisfied with the outcome after follow up of 12 months.

show abstract

“…(2) local microenvironment modification by production of cytokines, chemokines and factors to stimulate endogenous regeneration; (3) reduction or prevention of autoimmunity to beta cells (Ezquer, 2014 …”

Section: Mesenchymal Stem Cell Transplantation For Diabetes Mellitusmentioning

confidence: 99%

Mesenchymal stem cells for diabetes mellitus treatment: new advances

2017

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are the most widely used stem cells of the human body due to ease of successful isolation and expansion for many years. In particular, from 2012 until now, MSCs have been widely clinically used to treat various diseases, including graft versus host disease (GVHD), Crohn's disease, and knee osteoarthritis. In this review, the applications of MSCs in diabetes will be reviewed and discussed. Diabetes mellitus type 1, also known as Type 1 diabetes (T1DM), is an autoimmune disease in which immune cells attack the beta cells in islets of Langerhans (pancreatic islets). Although type 2 diabetes (T2DM) is considered to be a disease related to insulin resistance, several recent studies have shown some relation of immune dysfunction in this disease. Therefore, MSC transplantation may be a beneficial treatment for both T1DM and T2DM. MSC transplantation in preclinical trials and clinical trials for T1DM and T2DM have shown a moderate to significant improvement in diabetes without adverse side effects. In this review, we will discuss some of the updates from preclinical and clinical trials of MSC transplantation for diabetes.

show abstract

Mesenchymal Stem Cell Therapy in Type 1 Diabetes Mellitus and Its Main Complications: From Experimental Findings to Clinical Practice

Cited by 19 publications

References 143 publications

Human Dental Pulp Stem Cells – A Prospective Regenerative Therapy

Human Dental Pulp Stem Cells – A Prospective Regenerative Therapy

Therapeutic Application of Autologous ADMSCS (Adipose Derived Mesenchymal Stem Cells) and Islet like Cell Aggregates (ICAS) Derived from them in Type 1 and 2 Diabetes Mellitus - A Proof of Concept Study

Mesenchymal stem cells for diabetes mellitus treatment: new advances

Contact Info

Product

Resources

About